Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 274

1.

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.

Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID.

Breast Cancer Res Treat. 2005 Nov;94(1):37-46.

PMID:
16142439
[PubMed - indexed for MEDLINE]
2.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

J Cell Biochem. 2008 Feb 1;103(2):624-35.

PMID:
17562544
[PubMed - indexed for MEDLINE]
3.

Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.

Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID.

Prostate. 2008 Aug 1;68(11):1232-40. doi: 10.1002/pros.20789.

PMID:
18491370
[PubMed - indexed for MEDLINE]
4.

Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling.

Li F, Pham JD, Anderson MO, Youngren JF.

Eur J Pharmacol. 2009 Aug 15;616(1-3):31-7. doi: 10.1016/j.ejphar.2009.06.012. Epub 2009 Jun 17.

PMID:
19540220
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.

McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.

J Surg Res. 2006 May 15;132(2):208-13. Epub 2006 Mar 31.

PMID:
16580691
[PubMed - indexed for MEDLINE]
6.

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.

Breast Cancer Res. 2005;7(5):R708-18. Epub 2005 Jul 6.

PMID:
16168116
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.

Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF.

Mol Cancer Ther. 2006 Apr;5(4):1079-86.

PMID:
16648580
[PubMed - indexed for MEDLINE]
Free Article
8.

Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.

Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M.

Mol Cancer Ther. 2006 Feb;5(2):317-28.

PMID:
16505105
[PubMed - indexed for MEDLINE]
Free Article
9.

Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.

Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM.

J Cell Biochem. 2007 Dec 15;102(6):1529-41.

PMID:
17486636
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.

Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J.

Clin Cancer Res. 1997 Nov;3(11):2099-106.

PMID:
9815602
[PubMed - indexed for MEDLINE]
Free Article
11.

Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.

Chakravarti B, Siddiqui JA, Dwivedi SK, Deshpande S, Samanta K, Bhatta RS, Panda G, Prabhakar YS, Konwar R, Sanyal S, Chattopadhyay N.

Mol Cell Endocrinol. 2011 May 16;338(1-2):68-78. doi: 10.1016/j.mce.2011.03.012. Epub 2011 Mar 30.

PMID:
21457754
[PubMed - indexed for MEDLINE]
12.
13.

Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.

Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK.

Mol Cancer Ther. 2007 Jul;6(7):1973-82.

PMID:
17620428
[PubMed - indexed for MEDLINE]
Free Article
14.
15.
16.

mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.

Zhang Y, Xu S, Lin J, Yao G, Han Z, Liang B, Zou Z, Chen Z, Song Q, Dai Y, Gao T, Liu A, Bai X.

Breast Cancer Res Treat. 2012 Nov;136(2):379-88. doi: 10.1007/s10549-012-2270-7. Epub 2012 Sep 29.

PMID:
23053656
[PubMed - indexed for MEDLINE]
17.
18.

Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.

Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):4026-9. Epub 2007 Apr 29.

PMID:
17502145
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C.

Cancer Res. 2006 Jan 1;66(1):362-71.

PMID:
16397250
[PubMed - indexed for MEDLINE]
Free Article
20.

Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.

Zhou NN, Tang J, Chen WD, Feng GK, Xie BF, Liu ZC, Yang D, Zhu XF.

Life Sci. 2012 May 22;90(19-20):770-5. doi: 10.1016/j.lfs.2012.03.035. Epub 2012 Apr 13.

PMID:
22525372
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk